Psilocybin Research: A Comprehensive Overview
An animated video overview of current psilocybin research, covering clinical outcomes, mystical-type experiences, safety considerations, microdosing models, species identification, and emerging therapeutic applications. Based on 8 peer-reviewed studies sourced from Google Scholar.
Source Research Papers
Citations in APA 7 format. All studies were sourced from peer-reviewed journals via Google Scholar.
Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2017). Neuroticism is associated with challenging experiences with psilocybin mushrooms. Personality and Individual Differences, 117, 155–160. https://doi.org/10.1016/j.paid.2017.06.004
Bradshaw, A. J., Backman, T. A., Ramírez-Cruz, V., Forrister, D. L., Winter, J. M., Guzmán-Dávalos, L., Furci, G., Stamets, P., & Dentinger, B. T. M. (2022). DNA authentication and chemical analysis of Psilocybe mushrooms reveal widespread misdeterminations in fungaria and inconsistencies in metabolites. Applied and Environmental Microbiology, 88(24), e01498-22. https://doi.org/10.1128/aem.01498-22
Chopra, H., Furnish, T., Verduzco-Gutierrez, M., Jevotovsky, D. S., & Castellanos, J. (2024). Long-COVID symptoms improved after MDMA and psilocybin therapy: A case report. Clinical Case Reports, 12, e8791. https://doi.org/10.1002/ccr3.8791
Crowe, M., Manuel, J., Carlyle, D., & Lacey, C. (2023). Experiences of psilocybin treatment for clinical conditions: A qualitative meta-synthesis. International Journal of Mental Health Nursing, 32(4), 1025–1037. https://doi.org/10.1111/inm.13127
Hughes, J., Stuart-Bennett, J., Dunning, M., & Farrimond, H. (2024). Towards a dynamic processual model of psychedelic microdosing. International Journal of Drug Policy, 136, 104691. https://doi.org/10.1016/j.drugpo.2024.104691
James, E., Robertshaw, T. L., Hoskins, M., & Sessa, B. (2020). Psilocybin occasioned mystical-type experiences. Human Psychopharmacology: Clinical and Experimental, 35(5), e2742. https://doi.org/10.1002/hup.2742
Morton, E., Sakai, K., Ashtari, A., Pleet, M., Michalak, E. E., & Woolley, J. (2023). Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of 'magic mushroom' consumption. Journal of Psychopharmacology, 37(1), 49–60. https://doi.org/10.1177/02698811221131997
Nicholas, C. R., Henriquez, K. M., Gassman, M. C., Cooper, K. M., Muller, D., Hetzel, S., Brown, R. T., Cozzi, N. V., Thomas, C., & Hutson, P. R. (2018). High dose psilocybin is associated with positive subjective effects in healthy volunteers. Journal of Psychopharmacology, 32(7), 770–778. https://doi.org/10.1177/0269881118780713